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http://www.molecular-cancer.com/content/13/1/245RESEARCH Open AccessMCRS1 overexpression, which is specifically
inhibited by miR-129*, promotes the
epithelial-mesenchymal transition and metastasis
in non-small cell lung cancer
Min-Xia Liu1,2†, Ke-Cheng Zhou1,2† and Yi Cao1*Abstract
Background: Although tumor invasion and metastasis are both classical hallmarks of cancer malignancy and the
major causes of poor clinical outcomes among cancer patients, the underlying master regulators of invasion and
metastasis remain largely unknown. In this study, we observed that an overexpression of microspherule protein 1
(MCRS1) promotes the invasion and metastasis of non-small cell lung cancer (NSCLC) cells. Furthermore, we sought
to systematically investigate the pathophysiological functions and related mechanisms of MCRS1.
Methods: Retrovirus-mediated RNA interference was employed to knockdown MCRS1 expression in NSCLC cell
lines. Quantitative real-time polymerase chain reaction (qRT-PCR) and western blot respectively were used to
measure levels of mRNA and protein. Further cell permeability assessment, invasion and proliferation assays were
conducted to evaluate MCRS1 functions in vitro while nude mice experiments were performed to examine
metastatic capability in vivo. Microarray analysis and microRNA (miRNA) sequencing were respectively carried out
for mRNA and miRNA expression profiling, while chromatin immunoprecipitation (ChIP), luciferase reporter assay,
and miRNA transfection were used to investigate the interaction between MCRS1 and miRNAs.
Results: MCRS1 knockdown induced morphological alterations, increased monolayer integrity, decreased cellular
invasion and metastasis, and attenuated stemness and drug resistance among tested NSCLC cells. The levels of MCRS1
expression were likewise correlated with tumor metastasis among NSCLC patients. We identified differentially
expressed genes after MCRS1 silencing, which included cell junction molecules, such as ZO-1, Occludin, E-cadherin,
and DSG2. However, these differentially expressed genes were not directly recognized by a transcriptional complex
containing MCRS1. Furthermore, we found that MCRS1 binds to the miR-155 promoter and regulates its expression, as
well as MCRS1 promotes epithelial-mesenchymal transition (EMT), invasion, and metastasis through the up-regulation
of miR-155. Systematic investigations ultimately showed that MCRS1 was directly and negatively regulated by the
binding of miR-129* to its 3’-UTR, with miR-129* overexpression suppressing the growth and invasion of NSCLC cells.
Conclusions: MiR-129* down-regulation induced MCRS1 overexpression, which promotes EMT and invasion/metastasis
of NSCLC cells through both the up-regulation of miR-155 and down-regulation of cell junction molecules. This miR-129*
/MCRS1/miR-155 axis provides a new angle in understanding the basis for the invasion and metastasis of lung cancer.
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Lung cancer is one of the most common malignancies and
the leading cause of cancer-related death in the world.
Non-small cell lung cancer (NSCLC) comprises approxi-
mately 80% of all lung cancers. Lung cancer initiation and
progression are predominately driven by genetic alterations
in oncogenes and tumor suppressor genes [1]. Although
significant progress had been made in the discovery of lung
cancer-related genes, the pathophysiological functions and
mechanisms underlying these aberrant genes remain un-
clear. In previous studies, we observed a chromosome
12q13 abnormality [2] and further investigated the expres-
sion of 20 genes within the 12q13 region, observing the
overexpression of microspherule protein 1 (MCRS1) in
NSCLC cells [3]. MCRS1, also known as p78 and MSP58,
was initially identified as an interacting partner of nucleolar
protein p120 [4]. MCRS1 participates in the regulation of
gene transcription by interacting with various proteins, in-
cluding nucleolar proteins, transcription factors, and RNA-
binding proteins [4-7]. TOJ3 (a quail homolog of MCRS1)
behaves as an oncogene during fibroblast transformation,
and this transformation activity can be suppressed by the
tumor suppressor PTEN [8,9]. MCRS1 overexpression
has been documented in a variety of human cancers,
and this overexpression was found to induce the prolif-
eration of cancer cells [3,10-12]. In the present study,
we observed that MCRS1 overexpression promoted the
epithelial-mesenchymal transition (EMT) and metastasis
in NSCLC cells.
EMT and its reverse process, the mesenchymal-epithelial
transition (MET), are key programs in embryogenesis. Dur-
ing the EMT process, epithelial cells lose their characteris-
tics, such as cell-cell contacts and polarity, and adopt a
mesenchymal phenotype of increased migratory behavior.
Over the past decades, growing evidence has demonstrated
that EMT contributes to cancer development and metasta-
sis [13]. Moreover, EMT can result in drug resistance in
cancer cells and the acquisition of stem-like cells [14]. The
molecular mechanisms of EMT involve many aspects,
including transcription factors, cellular junctions, cytoskel-
eton, and microRNAs (miRNAs). Here, we explore the
mechanisms by which MCRS1 contributes to the EMT
program.
MCRS1 overexpression has been documented in a variety
of human tumors [3,10-12]; however, the molecular mecha-
nisms underlying MCRS1 alteration remain elusive. In this
study, we investigated the mechanisms of MCRS1 regula-
tion in NSCLC cells.
Results
MCRS1 depletion reverses EMT in lung cancer cells
The levels of MCRS1 expression were first determined in 7
lung cancer cell lines and 16HBE. There is no significant
difference in the expression of MCRS1 among the 7 NSCLCcell lines (Additional file 1a). EPLC-32 M1 and NCI-H292
that displayed very high levels of MCRS1 protein, were used
for MCRS1 knockdown. We stably reduced the MCRS1
expression in the EPLC-32 M1 and NCI-H292 using RNA
interference mediated by a retroviral system (pSIREN-
RetroQ), and the decreased expression of MCRS1 was
examined using quantitative Real-Time Polymerase Chain
Reaction (qRT-PCR) and western blot (Additional file 1b, c).
Characteristic MET morphological changes were ob-
served in the EPLC-32 M1 after MCRS1 depletion,
whereby the typical spindle-like appearance of fibroblast
cells was replaced with the round shape, epithelial morph-
ology under phase-contrast microscopy (Figure 1a Left).
Following TRITC-phalloidin staining for F-actin, the
MCRS1-silenced cells exhibited cortical bundles compared
to the control cells, which displayed contractile bundles,
indicating that MCRS1 overexpression could affect cyto-
skeletal rearrangement (Figure 1a Right). In the meantime,
reduced cell size was observed in MCRS1-depleted cells.
As dramatic changes in cell shape were observed after
MCRS1 depletion, we assessed the influence of MCRS1 on
cellular invasion and junctions. MCRS1 suppression signifi-
cantly reduced cell invasion, as assessed using a Transwell
invasion assay (Figure 1b, 1c). Additionally, to measure the
junction integrity, we performed cell permeability assays
based on the Boyden chamber using horseradish peroxidase
(HRP) as a tracer [15]. Silencing MCRS1 in the EPLC-32
M1 and NCI-H292 significantly reduced the permeability
of the cells to HRP, indicating that MCRS1 overexpression
could disrupt the functions of tight junctions (TJs)
(Figure 1d). Furthermore, we examined key molecules related
to EMT characteristics at the protein level. As shown in
Figure 1e, the cells depleted of MCRS1 had higher levels of
epithelial markers such as ZO-1, Occludin, and E-cadherin,
as well as a lower level of Vimentin (mesenchymal maker).
To confirm the role of MCRS1 in the EMT program, we
chose the 16HBE cells with the lowest level of MCRS1
expression as an in vitro model, and then treated 16HBE
with TGF-β1, the main inducer of EMT [13]. As anti-
cipated, the induced cells acquired the appearance of
mesenchymal-like cells, exhibited the increased expression
of MCRS1 and Vimentin as well as the reduced expression
of E-cadherin (Figure 1f, 1g). Additionally, we performed
MCRS1 knockdown in TGF-β1 treated cells, and found
that MCRS1-shRNA depletion could reverse functions of
TGF-β1 treatment and lead to an increased expression of
E-cadherin and a decreased expression of Vimentin
(Figure 1g). These results indicated that MCRS1 deregula-
tion may be involved in the EMT program.
Taken together, the changes in cellular morphology,
permeability, and invasion and alterations in the expression
of EMT-related molecules after MCRS1 silencing demon-
strated that MCRS1 could contribute to the EMT program
in NSCLC cells.
Figure 1 Results of the morphological and functional experiments in NSCLC cells after MCRS1 silencing. (a) Left: Morphological observation of
EPLC-32 M1 cells using phase-contrast microscopy. Right: Images of F-actin stained EPLC-32 M1 cells. (b and c) The results of the matrigel invasion assays
in EPLC-32 M1 and NCI-H292 cells with or without MCRS1 knockdown. The invaded cells are stained with crystal violet (b), and the fold change in the
number of invading cells is given as the mean ± SD from three independent experiments (c). (d) Cell permeability assay of the EPLC-32 M1 and NCI-H292
cells with or without MCRS1 silencing. The values of HRP permeability are given as the mean ± SD. (e) Western blot analysis of ZO-1, Occludin, E-cadherin
and Vimentin in EPLC-32 M1 and NCI-H292 cells with or without MCRS1 depletion. (f) Morphological changes in 16HBE cells treated by TGF-β (ΔTGF-β)
after transient MCRS1 knockdown (ΔMCRS1). (g) Western blot analysis of MCRS1, E-cadherin,and Vimentin in 16HBE cells treated by TGF-β (ΔTGF-β) after
transient MCRS1 knockdown (ΔMCRS1). Luc: cells without MCRS1 silencing; Msh3: cells with stable MCRS1 silencing; *P <0.05 (Student’s t-test).
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and the generation of CSC-like cells from NSCLC cells
As shown in Figure 2a and 2b, compared with MCRS1
depletion alone (no drug treatment) and the drugtreatments alone (no MCRS1 depletion), MCRS1 silencing
significantly inhibited the growth of EPLC-32 M1 and NCI-
H292 after treatments with cisplatin (a common chemo-
therapy drug for NSCLC treatment) and cetuximab (a
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cancer). Furthermore, MCRS1 suppression significantly
decreased mRNA expression of ABCB1 (multidrug
resistance gene, Figure 2c) [16]. Collectively, these
observations indicated that MCRS1 overexpression could
trigger drug resistance.
We also analyzed the expression of the putative cancer
stem cell (CSC) marker CD44 [17]. As determined by flow
cytometric analysis, both EPLC-32 M1 and NCI-H292
exhibited lower levels of CD44 expression after MCRS1
silencing (Figure 2d).MCRS1 silencing inhibits tumor metastasis in an
experimental animal model
To determine whether the abnormal expression of MCRS1
could initiate tumor metastasis in vivo, MCRS1-depleted
cells and control cells were injected into nude mice
through the lateral tail vein. As shown in Figure 3a, the
mice injected with the MCRS1-depleted EPLC-32 M1 dis-
played a small number of visible metastatic nodules in the
lung and brain compared to the corresponding control
group. The metastases in the lung and brain were
confirmed by histological examination (Figure 3b), and a
statistical analysis revealed that MCRS1 silencing dramat-
ically attenuated the ability of the cancer cells to form
metastases in the lung and brain (Figure 3c). Similar
results were also found in the NCI-H292 after MCRS1
knockdown. Taken together, these findings demonstrated
that MCRS1 overexpression strongly promoted the metas-
tasis of NSCLC cells in vivo.Figure 2 The drug resistance and generation of CD44+ CSC-like cells
the viability of EPLC-32 M1 and NCI-H292 cells after cisplatin treatment for
cetuximab treatment for 72 h. (c) The expression of ABCB1 mRNA after MC
EPLC-32 M1 and NCI-H292 cells with or without MCRS1 knockdown. Luc: c
*P <0.05 (one-way ANOVA and Student’s t-test).The mRNA levels of MCRS1 are associated with tumor
metastasis in NSCLC patients
To investigate whether MCRS1 overexpression clinically
correlated with the metastatic capacity of NSCLC cells,
we conducted quantitative experiments (qRT-PCR) to
examine the MCRS1 expression level in 33 human tissue
samples, including 25 NSCLC samples (14 tumors with-
out metastasis and 11 tumors with lymph node and/or
blood metastasis) and 8 noncancerous lung samples. The
statistical analysis revealed that the MCRS1 mRNA levels
in the tumors with metastases were higher than in the
metastasis-free tumors or the noncancerous lung samples
(Figure 3d). Similar as the MCRS1 mRNA levels, the levels
of MCRS1 protein were also significantly higher in NSCLCs
with metastasis compared with NSCLCs without metastasis
by Western blot analysis (Figure 3e). Furthermore, we
examined levels of E-cadherin mRNA and protein in
human specimens, and found that values of E-cadherin in
NSCLCs with metastases were markedly lower than in
NSCLCs without metastases (Figure 3e, 3f). The correlation
analysis revealed a negative relationship between MCRS1
and E-cadherin expressions in NSCLC tissues (Figure 3g).
Collectively, MCRS1 expressions were associated with the
status of tumor metastasis in clinical samples.
The mRNA expression scan identified differentially
expressed genes after MCRS1 knockdown
To explore the molecular effectors associated with MCRS1
activity, we performed a microarray analysis to determine
the mRNA profiles of EPLC-32 M1 following MCRS1
knockdown. The results revealed that 237 and 132 genesin cultured NSCLC cells after MCRS1 silencing. (a) Assessment of
72 h. (b) Assessment of the viability of EPLC-32 M1 and NCI-H292 after
RS1 depletion. (d) Flow cytometric analysis of CD44 expression in
ells without MCRS1 silencing; Msh3: cells with stable MCRS1 silencing.
Figure 3 (See legend on next page.)
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Figure 3 MCRS1 expression promoted tumor metastasis in NSCLC cells. a-c: Assessment of tumor metastasis of EPLC-32 M1 cells with and
without MCRS1 silencing in nude mice. (a) Morphological observation of lung and brain metastases. (b) Histopathological observation of representative
lung and brain sections, arrow: metastatic cancer cells. (c) The number of metastatic nodules in the lung and brain were counted and analyzed. (d) The
relative expressions of MCRS1 mRNA in three groups of 33 tissue sample, including 8 noncancerous tissues, 14 NSCLCs without metastasis, and 11 NSCLCs
with metastasis. (e) The expression of MCRS1 and E-cadherin proteins in clinical samples. N: Noncancerous; NM: No metastasis; M: Metastasis. (f) The
relationship between the E-cadherin mRNA expression and the status of tumor metastasis. (g) The inverse correlation relationship between the MCRS1 and
E-cadherin expression (Pearson’s method, R =−0.438). Luc: cells without MCRS1 silencing; Msh3: cells with stable MCRS1 silencing. Noncancerous: patient
with no cancer. No metastasis: patients without any metastases. Metastasis: patients with lymph node metastases and/or blood spread. *P <0.05 (one-way
ANOVA and Student’s t-test).
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MCRS1 silencing. Through a bioinformatics analysis using
Gene Ontology (GO) terms, the genes regulated by MCRS1
were grouped into several categories (Additional file 2).
Additionally, using a Kyoto Encyclopedia of Genes and
Genomes (KEGG) analysis we were particularly interested in
how cell junctions and Notch signaling were affected by
MCRS1 due to their potential roles in EMT and tumor me-
tastasis (Figure 4a, Additional file 3). The expression levels
of EMT-related molecules, such as ZO-1 (TJP1), Occludin
(OCLN), desmoglein 2 (DSG2), E-cadherin (CDH1), ITGA6,
Notch 3 (NOTCH3) and Vimentin (VIM), were verified by
qRT-PCR (Figure 4b, 4c). Subsequently, we investigated the
relationship between MCRS1 and its downstream molecules
(ZO-1, Occludin, E-cadherin, DSG-2). Through bioinfor-
matics analysis and prediction, MCRS1 could not directly
bind the promoters of these downstream molecules. Using
chromatin immunoprecipitation (ChIP) assay, we also did
not find that MCRS1 bound directly the promoters of these
genes (Additional file 4). Based on these data, MCRS1 may
regulate the expressions of the genes related to cell
junctions and the Notch pathway, however, those genes
were not directly recognized by a transcriptional complex
containingMCRS1.
MCRS1 significantly increase the expression of miR-155 in
NSCLC cell lines
MiRNAs are small non-coding RNAs that regulate gene
expression via either translation inhibition or mRNA deg-
radation [18], and have been shown to have both pro- and
anti-metastatic effects [18-20]. To gain further insight into
whether MCRS1 regulates EMT and tumor metastasis
through miRNAs, we primarily determined the miRNA
profiles in the EPLC-32 M1 with and without MCRS1
silencing. This research strategy is demonstrated in
Figure 5a. In total, 26 known miRNAs and 29 novel
miRNAs were differentially expressed after MCRS1 silen-
cing (Additional file 5 and Additional file 6), with miR-155,
miR-210, and miR-383 as the most affected. As these 3
miRNAs have been reported to be involved in tumor
development and progression [21-23], we selected them
for further investigation.
QRT-PCR validation of the three candidate miRNAs
demonstrated that miR-155 expression was significantlyup-regulated in the NSCLC cell lines (Figure 5b) and
NSCLC tissues (Figure 5c). Because MCRS1 is a transcrip-
tion factor and may target the promoter of the miR-155
host gene (MIR155HG) through bioinformatic prediction
(Figure 5d Left), we performed a ChIP to determine
whether MCRS1 is targeted to the miR-155 promoter.
Indeed, the ChIP results demonstrated that MCRS1 was
bound to the promoter region of the miR-155 gene
(Figure 5d Right). Moreover, the expression of miR-155 was
markedly attenuated in the EPLC-32 M1 and NCI-H292
after MCRS1 silencing (Figure 5e, Additional file 7).
A previous study showed that miR-155 induced EMT
by targeting RhoA at the post-transcriptional level [24].
In this study, we found that RhoA is a target of miR-155
in EPLC-32 M1 and NCI-H292, with the expression of
RhoA protein being up-regulated after MCRS1 silencing
(Figure 5f, 5g). Furthermore, the treatment with miR-155
mimic significantly rescued the cellular proliferation and
invasion abilities in MCRS1-depleted cells, whereas miR-155
down-regulation abrogated the effects of MCRS1 in the con-
trol cells (Figure 5h, 5i). In clinical samples (6 noncancer-
ous lung tissue, 8 NSCLCs without metastasis, and 7
NSCLCs with metastasis), levels of miR-155 were associ-
ated with the status of tumor metastasis (Figure 5j). Sum-
marily, these data suggested that miR-155 could be a
downstream node of MCRS1 in the development and pro-
gression of NSCLC.
MCRS1 is directly regulated by miR-129* (miR-129-1-3p)
in lung cancer cells
Many oncogenes and tumor suppressor genes are regulated
by miRNAs [18]. Thus, to identify miRNAs that may regu-
late MCRS1 expression, miRNA profiles were determined
in the NSCLC cell lines (EPLC-32 M1, A549, and 801D)
and 16HBE. Compared with 16HBE, in total, 87 consensus
miRNAs were differentially expressed in NSCLC cells
(Additional file 8). We then used the miRWalk web tool to
predict seven miRNAs that target MCRS1 (Additional file
9). The research strategy is described in Additional file 10,
and miR-129* and miR-1299 were identified as candidates.
We examined the expression of these miRNAs in a series
of lung cancer cell lines and found that the expression of
miR-129* correlated inversely with MCRS1 expression
(Figure 6a). Moreover, we confirmed the data from the
Figure 4 Differentially expressed genes related to EMT process after MCRS1 silencing. (a) A mRNA microarray analysis of the expression
changes of genes related to EMT in EPLC-32 M1 cells following stable MCRS1 knockdown. +, up-regulation; −, down-regulation. (b, c) qRT-PCR
validation of differentially expressed genes with and without MCRS1 knockdown in EPLC-32 M1 and NCI-H292 cells. Luc: cells without MCRS1
silencing; Msh3: cells with stable MCRS1 silencing. The results were analyzed by student’s t-test (P <0.05).
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lung tissues. As shown in Figure 6b and 6c, miR-129* was
remarkably down-regulated in the NSCLC tissues and ap-
peared to be inversely correlated with MCRS1 mRNA
expression.
To test whether MCRS1 is a direct target of miR-129*,
we performed a luciferase reporter assay by constructing
reporter genes containing the MCRS1 3’-UTR and found
that the luminescence intensity was significantly reduced
following the addition of a miR-129* mimic (Figure 6d).
The forced expression of miR-129* significantly suppressed
MCRS1 expression at both the mRNA and protein levels(Figure 6e, 6f). Altogether, these data strongly suggest that
MCRS1 was directly regulated by miR-129* in the NSCLC
cells.
Considering the novel discovery of miR-129* in NSCLC,
we assessed the potential effects of miR-129* on EMT
process. The forced expression of miRNA-129* significantly
induced the up-regulation of E-cadherin (epithelial marker)
and down-regulation of Vimentin (mesenchymal marker)
at both mRNA and protein levels (Figure 6e, 6f). Moreover,
the ectopic expression of miRNA-129* significantly reduced
cellular proliferation (Figure 6g) and invasion (Figure 6h).
Additionally, miR-129* expressions were analyzed in
Figure 5 MCRS1 promoted EMT through the up-regulation of miR-155. (a) Screening strategy of miR-155. (b) The relative expression of
miR-155 in NSCLC cell lines. (c) The level of miR-155 in clinical samples including 6 noncancerous lung tissue and 15 NSCLC tissues (Student’s t-test,
*P <0.05). (d) Left: The map of miR-155 host gene (MIR155HG). Right: miR-155 was identified as a downstream target of MCRS1 using ChIP analysis;
normal mouse IgG was used as the immunoprecipitation negative control. Input and immunoprecipitated DNAs were analyzed by PCR using primers
specific for the promoter of the miR-155 host gene (MIR155HG). (e) miR-155 expression in EPLC-32 M1 and NCI-H292 cells with and without MCRS1
silencing. (f) Protein expression of RhoA (a target of miR-155) in EPLC-32 M1 and NCI-H292 cells after miR-155 treatment. (g) Protein expression of RhoA
in EPLC-32 M1 and NCI-H292 cells with and without MCRS1 silencing. (h, i) The miR-155 inhibitor (miR-155 ASO) treatment decreased cell growth
and invasion in cancer cells without MCRS1 silencing, and the miR-155 mimic treatment rescued the effects of MCRS1 with regard to cell growth and
invasion in MCRS1–depleted cells. (j) The relationship between the level of miR-155 expression and the status of tumor metastasis (*P <0.05;
one-way ANOVA and Student’s t-test). Luc: cells without MCRS1 silencing; Msh3: cells with stable MCRS1 silencing; NC: negative control. ASO:
antisense oligonucleotide. Noncancerous: noncancerous lung tissues; No metastasis: NSCLCs without metastasis; Metastasis: NSCLCs
with metastasis.
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Figure 6 miR-129* directly regulated MCRS1 expression in NSCLC cells. (a) Expression of MCRS1 and miR-129* in NSCLC cell lines. (b) The
level of miR-129* in clinical samples (Student’s t-test, *P <0.05). (c) Correlation analysis of miR-129* and MCRS1 mRNA levels in NSCLC tissues
(Pearson’s method, R = −0.513, *P <0.05). (d) Top: MCRS1 was predicted as a target of miR-129*. Bottom: Validation of the direct targeting of
MCRS1 by miR-129* using a luciferase reporter assay (Student’s t-test, *P <0.05). (e and f) Relative mRNA and protein expressions of MCRS1,
E-cadherin, and Vimentin in cells transfected with the miR-129* mimic or mimic NC (Student’s t-test, *P <0.05). MTT assays (g) and matrigel
invasion assays (h) of EPLC-32 M1 and NCI-H292 cells transfected with the miR-129* mimic or mimic NC (Student’s t-test, *P <0.05). (i) The
relationship between the level of miR-129* expression and the status of tumor metastasis (*P <0.05; one-way ANOVA and Student’s t-test). NC:
negative control; Noncancerous: noncancerous lung tissues; No metastasis: NSCLCs without metastasis; Metastasis: NSCLCs with metastasis.
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8 NSCLCs without metastasis, and 7 NSCLCs with metas-
tasis. As shown in Figure 6i, the value of miR-129* expres-
sion were related with the status of tumor metastasis.
Summarily, these data demonstrated that miR-129* could
be a tumor suppressor that affects cellular behavior by
modulating MCRS1 expression.
Discussion
Tumor invasion and metastasis have been identified as
classical hallmarks of cancer malignancy. Metastatic
dissemination, disease relapse, and drug resistance are
major causes of a poor clinical outcome in cancer patients,
and strong evidence has demonstrated that these processes
are closely associated with the EMT program [13,14]. The
present study is the first to demonstrate that MCRS1 is a
regulator of the EMT program in NSCLC cells. We con-
firmed this finding by providing the following evidence. 1)
EPLC-32 M1, a highly invasive lung cell line, underwent a
morphological change from a spindle-like shape to a round
shape after MCRS1 silencing. 2) MCRS1 depletion inhib-
ited cellular invasion and reduced monolayer permeability
in vitro. 3) MCRS1 depletion resulted in the up-regulated
expression of ZO-1 and Occludin and E-cadherin, core-
constituent molecules of epithelial TJs and adherent junc-
tions (AJs), respectively, which mediate the organization of
these junctions. The down-regulation of epithelial junction
molecules has been generally accepted as a hallmark of
EMT and has also been shown to directly contribute to the
invasion of cancer cells [13], and the destruction of TJs can
increase epithelial permeability. 4) The metastatic capacity
of NSCLC cells was attenuated by MCRS1 depletion in vivo,
and MCRS1 mRNA expression was associated with tumor
metastasis in NSCLC patients. 5) TGF-β treatment simul-
taneously induced MCRS1 up-regulation and the EMT pro-
gram in 16HBE. 6) The down-regulation of MCRS1 in
NSCLC cells increased the sensitivity of these cells to
cisplatin and cetuximab, and decreased the CD44-positive
CSC-like cell population. Accumulating evidence has
suggested that EMT contributes to the drug resistance and
the acquisition of stem cell-like properties [14]. These obser-
vations could be considered as additional proofs that
MCRS1 overexpression promotes the EMT in NSCLCs. In
summary, MCRS1 overexpression contributes to the EMTprogram in NSCLC cells, and this EMT program may be
involved in tumor metastasis. Because metastasis is a very
significant factor in the clinical prognosis of patients and
MCRS1 overexpression was observed in almost all NSCLC
tissues, we speculate that therapies directed at preventing
the EMT program mediated by MCRS1 might be a potential
treatment for NSCLC, an avenue that is worthy of further
study.
To clarify the downstream effectors of MCRS1 in
NSCLC, we compared the mRNA expression profiles of
cultured cells with or without MCRS1 silencing. The differ-
entially expressed genes were mainly involved in cell cycle,
proliferation, apoptosis, EMT process and invasion. The
differentially expressed genes which are associated with cell
proliferation, included MAPK, P53, Bcl-2, CDK4/6, Cyclin
A/B, and so on. In previous study, we found that MCRS1
induced the proliferation of NSCLC [3]. We thought that
these differentially expressed genes related to proliferation
might be involved in mechanisms by which MCRS1
contributes to the proliferation of NSCLC. Here, we
focused on the differentially expressed genes related to
EMT process and metastasis. These differentially expressed
genes directly related to the EMT program, cellular inva-
sion, and tumor metastasis were grouped into the following
families: cell-cell adhesion, cell-extracellular matrix protein
(ECM) adhesion, stemness, cellular junctions, and Notch
signaling. Surprisingly, the classical EMT transcription
factors (Snail, Twist, and Slug) were not found to be differ-
entially expressed. Several molecules related to EMT are
discussed below. 1) Occludin and ZO-1 are a transmem-
brane protein and a cytoplasmic plaque protein at TJs,
respectively, and both play important roles in maintaining
the TJ structure and function. TJs contribute to cell-cell
attachment and maintain epithelial cell integrity and
polarity [25], and the destruction of TJs can increase epi-
thelial permeability and cellular invasion, promoting tumor
metastasis [26]. In our study, MCRS1 overexpression in-
creased epithelial permeability and reduced both ZO-1 and
Occludin expression (Figure 1d, 1e), indicating that MCRS1
overexpression may abolish the functions of TJs and pro-
mote cellular invasion and tumor metastasis through the
suppression of TJ molecules. 2) E-cadherin is the major
transmembrane protein of AJs and mediates Ca2
+-dependent cell-cell adhesion; the loss of E-cadherin
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metastasis [27]. In our study, E-cadherin was found to be
up-regulated at both the mRNA and protein levels after
MCRS1 knockdown, suggesting that MCRS1 overexpres-
sion can lead to AJ disruption, cellular invasion, and tumor
metastasis. 3) DSG2 is a transmembrane protein found in
desmosomes and plays an important role in cell adhesion
[28], the loss of which facilitates the EMT program and
tumor metastasis [29]. We found that MCRS1 overexpres-
sion suppressed the expression of DSG2 mRNA, indicating
that MCRS1 overexpression could impair cell adhesion and
increase tumor invasion and metastasis. However, pro-
moters of ZO-1, Occludin, E-cadherin and DSG2 genes
were not directly recognized by a transcriptional complex
containing MCRS1. The mechanisms by which MCRS1
regulates these genes remain unresolved. We noted that
several molecules related to the EMT program were also
differentially expressed after MCRS1 silencing, including
ITGA6 and Notch3. The former is a marker of stems cells
that can enhance and maintain the stemness of cancer cells
[30]. The latter is a member of the Notch family of trans-
membrane receptors and can induce or suppress the EMT
program depending on the cancer type; Notch3 knock-
down was reported to result in the reduction of lung CSCs
[31]. Altogether, these results indicated that MCRS1 over-
expression can influence multiple molecules and pathways
and promote the EMT program, cellular invasion, and
tumor metastasis.
Emerging evidence has demonstrated that miRNAs play
vital roles in the regulation of various biological and
pathological processes, including the EMT program, cell
invasion, and tumor metastasis [18,20]. By assessing
miRNA expression profiles after MCRS1 depletion, we
found that miR-155 is a downstream effector of MCRS1.
Moreover, miR-155 was up-regulated in NSCLC tissues
and cultured cells, and its overexpression was correlated
with the MCRS1 expression and the status of tumor
metastasis. ChIP assay demonstrated that MCRS1 binds to
the miR-155 promoter. Our interference experiments also
confirmed that miR-155 expression could be induced by
MCRS1 over-expression. The forced expression of miR-155
recapitulated the effect of MCRS1 on cell growth and
invasion. MiR-155, which is known as an oncogenic
miRNA, is up-regulated in multiple human tumors and
plays functional roles in several aspects of tumor develop-
ment and progression [21,24,32]. In our study, the down-
regulation of miR-155 was found to reduce cellular growth
and invasion, and vice versa. However, the down-
regulation of miRNA-155 did not alter the expression of
ZO-1 and Occludin but did change the levels of E-
cadherin. Therefore, the down-regulation of the junction
molecules induced by MCRS1 was independent of miRNA-
155. Recent studies have shown that miR-155 mediates
TGF-β-induced EMT by targeting RhoA [24] and inducesbreast cancer EMT through the loss of C/EBPβ [33]. In the
present work, the expression levels of RhoA and E-cadherin
proteins were down-regulated after the miRNA-155 mimetic
treatment but were up-regulated after MCRS1 silencing.
Therefore, we hypothesize that miRNA-155 and RhoA may
be functional downstream mediators of the EMT program
mediated by MCRS1 in NSCLC cells. These findings
provide an additional molecular mechanism of the
pathophysiological functions of MCRS1.
Previous studies have demonstrated that many onco-
genes are potentially regulated by tumor suppressor
miRNAs [18]. To identify whether MCRS1 overexpression
is regulated by miRNAs, the miRNA profiles of cultured
NSCLC cells and immortalized human bronchial epithelial
cells were compared, and the differentially expressed
miRNAs were further analyzed using bioinformatic
methods to screen the candidates. Among the 7 selected
candidates, miR-129* expression was significantly down-
regulated and negatively correlated with MCRS1 expres-
sion in the NSCLC tissues and cultured cells. The value of
miR-129* was inversely correlated with the status of
tumor metastasis. Furthermore, MCRS1 expression was
regulated by the binding of miR-129* to the 3’-UTR
in vitro. Collectively, these results suggest that miR-129*
expression can suppress oncogenic MCRS1 expression in
NSCLC cells. MiR-129* originates from miR-129-1 at the
7q32.1 locus, which is a site commonly deleted in many
cancers [34]; indeed, a recent study indicated that the
expression of miR-129* is down-regulated in gastric can-
cer [35]. In our functional test, miR-129* overexpression
suppressed the cellular growth and invasion in NSCLC
cells. Based on these data, miR-129* could be a tumor
suppressor miRNA in NSCLC cells.
Conclusions
MCRS1 overexpression promoted the EMT program and
tumor invasion/metastasis in NSCLC cells through the
up-regulation of miR-155 and the down-regulation of cell
junction molecules. Additionally, MCRS1 activation was
mediated by miR-129* down-regulation. The miR-129*/
MCRS1/miR-155 axis provides a new avenue to under-
stand the mechanism of the tumor invasion and metasta-
sis (Figure 7).
Methods
Human tissue specimens and cell lines
Lung cancer tissues were obtained from 35 patients under-
going resection. No patients were treated before undergo-
ing surgery. The tumor samples were from primary tumors.
The metastatic status of patients was recorded on the basis
of the pathological and clinical examinations at the time of
resection. All of these samples were diagnosed according to
World Health Organization’s classification and staged based
on the International Union Against Cancer [36,37]. In total,
Figure 7 Proposed model of MCRS1 regulation and its
functional roles.
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and inflammatory pseudotumor through surgical oper-
ation, are used as “noncancerous tissues”. Our study was
approved by the local research ethics committee.
Details of all cell lines were provided in Additional file 11.
After 24 hours (h) serum starvation, 16HBE (an im-
mortalized human bronchial epithelial cell line) was
treated with TGF-β1 (Invitrogen, Carlsbad, CA, USA) at
15 ng/ml and cultured for 72 h. The transient MCRS1
interference was also carried out in TGF-β1 treated cells
as described previously [3].RNA interference
The target sequence (GCTGAAGAACAACGGTGAT)
was used for MCRS1 interference as described previously
[3]. Luciferase shRNA oligonucleotide served as a negative
control. The complementary strands of the oligonuleotides
were annealed and ligated into prelinearized RNAi-Ready
pSIREN-RetroQ vector (Clontech, Palo Alto, CA, USA).
Recombinant vectors were then cloned and transfected
into PT-67 cells using Lipofectamine 2000 (Invitrogen).
After 48 h transfection, the retrovirus–containing medium
was filtered and used to infect NSCLC cell lines in the
presence of 10ug/ml polybrene (Sigma, St. Louis, MO,
USA). After 48 h infection, the cells were selected by puro-
mycin selection (Sigma). Stable subcell-lines with MCRS1
knockdown and control cells were established to further
investigate.QRT–PCR
For mRNA expression assay, total RNA was isolated from
cells using the RNA-Pure kit (QIAGEN, Hilden, Germany).
The cDNA was synthesized by M-MLV Reverse Transcript-
ase (Promega, Madison, WI, USA) using random primer
and amplified with specific primers on the StepOne Realtime
PCR System (Applied Biosystems, Foster City, CA, USA).
For miRNA expression assay, total RNA was polyade-
nylated and reverse-transcribed into cDNA using the
miScript II RT kit (QIAGEN), and the qRT-PCR ana-
lysis was performed using the miScript SYBR Green PCR
kit (QIAGEN) according to the manufacturer’s instructions.
All primers in our research were listed in Additional file 12.
Western blot analysis
Cells were harvested and lysed in RIPA buffer (Beyotime
Biotechnology, Shanghai, China). Cell lysates were resolved
by 8-12% sodium dodecylsulfate polyacrylamide gel elec-
trophoresis (SDS-PAGE) and transferred onto PVDF
membranes (Millipore, Bedford, MA, USA). The mem-
brane was incubated with the specific antibodies and all
antibodies in our research were listed in Additional file 13.
Immunofluorescence staining and confocal microscopy
Cells grown on the glass coverslip were fixed in 3.7% for-
maldehyde solution, permeated with 0.1% Triton X-100,
blocked with 1% bovine serum albumin (BSA) in phos-
phate buffer saline (PBS), and incubated respectively with
rhodamine-conjugated phalloidin (Invitrogen) and DAPI
(Beyotime Biotechnology) to stain F-actin and nuclei. Then
cells were mounted with 50% glycerol and analyzed by
confocal laser scanning microscopy (Zeiss LSM510 Meta,
Germany).
Flow cytometric analysis
Expression of cancer stem-like cells markers was evalu-
ated by fluorescence activated cell sorting (FACS). Cells
were washed with 2% FBS in PBS and stained with
FITC-conjugated anti-CD44 antibody (BD Pharmingen,
San Diego, CA, USA). After the staining, cells were
washed again, resuspended and analyzed on a FACScan
flow cytometer (BD Biosciences, San Jose, CA, USA).
Cell monolayer integrity assessment
Cell monolayer integrity was assessed by measuring the
permeation of horseradish peroxidase (HRP, Sigma) using
the Boyden Chamber as our previously described [19].
Briefly, cells were cultured onto the upper chamber mem-
brane with 8 μm pore (BD Bioscience) to complete conflu-
ence. Then the medium in the lower and top chamber
was replaced with the fresh medium and medium contain-
ing HRP, respectively. The medium in the basal chamber
was harvested every 5 minutes (min) and transferred into
96-well plates. Then substrate solution (50 mM sodium
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drochloride, 0.003% H2O2) was added, followed by
addition of 0.1% sodium azide. Optical density was read
on a microplatereader at 450 nm.
Cell invasion assay
Cell invasion were performed using 24 transwell chamber
with matrigel-coated membrane (pore size = 8 μm; BD
Bioscience). 1 × 105 prepared cells were seeded in the
upper chamber and incubated for 18-24 h. After the non-
invasive cells were removed by a cotton swab, the invasive
cells were fixed in 4% paraformaldehyde and stained with
crystal violet. The stained cells were viewed and counted
using inverted microscope (Nikon, Tokyo, Japan).
Cell proliferation assay
Cell proliferation assay was based on 3-(4,5-dimethylthiazol-
2-yl)-2, 5-Diphenyltetrazolium bromide (MTT) methods.
Cells were seeded at a density of 4 × 103 cells /well in
96-well plates for 24 h. For cell growth assay, MTT was
added into each well. After the MTT incubation, the
medium was removed and followed by addition of Dimethyl
sulfoxide (DMSO). The absorbance was read at 570 nm
(630 nm as a reference) on a microplate reader (model 680,
Bio-Rad Laboratories).
For drug resistance assay, cells were maintained in culture
medium containing cisplatin (15 μM) or cetuximab (5 μg/
ml) for 72 h, and subsequently analyzed by cell proliferation
assay.
In vivo metastasis assay
Female BALB/c nude mice (4 weeks) were purchased from
Vital River Laboratories (Beijing, China) and housed under
standard condition. The animals were divided into two
groups of 6 mice each. The mice of the two groups were
implanted intravenously with MCRS1 knockdown cells and
control cells (1 × 106 in 0.2 ml PBS) into the lateral tail vein,
respectively. The tumors were excised, counted and histo-
pathologically examined by hematoxylin-eosin staining after
four weeks. All experiments were performed in accord-
ance with the regulation experimentation for animal and
approved by the responsible authorities.
mRNA/miRNA expression profiling
Total RNA was isolated using the Trizol reagent (Sigma)
following the manufacturer’s protocol. Determination of
mRNA profiling was performed in EPLC-32 M1 cells with
and without MCRS1 knockdown using Agilent 60 K
Human Gene Expression array by CapitalBio Corporation
(Beijing, China; http://www.capitalbio.com). The differen-
tially expressed genes were subjected to Gene Ontology
(GO) and Kyoto Encyclopedia of Genes and Genomes
(KEGG) pathway analyses using the Mas 3.0 molecule
annotation system (http://bioinfo.capitalbio.com/mas3).MiRNA expression profiling was determined in A549,
801D, and 16HBE, as well as EPLC-32 M1 cells with and
without MCRS1 knockdown using Hiseq 2000 platform
by BGI Tech (Shenzhen, China; http://bgitechsolutions.
com). The miRWalk database (http://www.umm.uni-
heidelberg.de/apps/zmf/mirwalk/micrornapredictedtarget.
html) was used to predict the target genes of the miRNAs
[38].Transient transfection of miRNA mimics or inhibiters
MiRNA mimics, 2’-O-methylated miRNA antisense oligonu-
cleotides (ASO), and their cognate controls were purchased
from RiBoBio Company (Guangzhou, China). The transfec-
tion was performed using Lipofectamine 2000 (Invitrogen)
following the manufacturer’s instructions. For the transfec-
tion, 100 nmol/L miRNA mimic and 150 nmol/L ASO were
used.ChIP assay
ChIP assays were performed using the EZ-Magna ChIP kit
(2165871; Millipore, Merck KGaA, Darmstadt, Germany)
according to manufacturer’s instructions. Briefly, 3 × 107
cells were collected and cross-linked with 1% formaldehyde
at room temperature for 10 min and then lysed in cell lysis
buffer containing protease inhibitor cocktail II. After centri-
fugation, the cell pellet were resuspended in nuclear lysis
buffer containing cocktail II and sonicated on ice to an
average length of approximately 250 bp with a Bioruptor
sonicator. The sonicated chromatin was then immunopre-
cipitated using an anti-MCRS1 antibody (Additional file 13)
or normal mouse IgG (the negative control) and protein G
magnetic beads overnight at 4°C with rotation. After
removing the supernatant using a magnetic separator
(Invitrogen), the protein/DNA complexes were washed
and eluted, and the crosslinks were reversed at 62°C. The
input and immunoprecipitated DNAs were purified using
Spin columns and then analyzed by PCR.MCRS1 3’-UTR construction and luciferase reporter assay
To obtain the luciferase construct, the full-length 3’-UTR
of MCRS1 (containing the binding sites for miR-129*) was
amplified from the genomic DNA of EPLC-32 M1 cells
and was inserted between the MluI and BgIII restriction
sites in the pGL-3 basic vector (Promega).
For the luciferase assays, a mixture of the pGL-3’-UTR
vector and Renilla luciferase plasmid (pRL-TK) was
cotransfected into the cells with the miR-129* mimic or
its negative control using Lipofectamine 2000. The pRL-
TK plasmid was used as an internal control. After trans-
fection, the luciferase activities were measured using
Dual-Luciferase Reporter System (Promega) according
to the manufacturer’s instructions.
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All the data are presented as the mean ± standard deviation
(SD) from at least three independent experiments. The data
were analyzed using SPSS 17.0 software package (Chicago,
IL, USA). The measurement data (levels of mRNA and
miRNA, HRP permeability, cell invasion and proliferation)
were analyzed by Student’s t-test or a one-way ANOVA, as
appropriate. The relationship between the miRNA levels
and gene expression was determined using Pearson’s correl-
ation coefficient test. The level of statistical significance was
set at 0.05 for all the tests.Additional files
Additional file 1: Expression of MCRS1 by western blotting and
qRT-PCR. (a) Results of MCRS1 protein in seven NSCLC cell lines and an
immortalized human bronchial epithelial cell line (16HBE). (b) Results of
MCRS1 protein in EPLC-32 M1 and NCI-H292 cells with (Msh3) and
without (Luc) MCRS1 knockdown. (c) Results of MCRS1 mRNA in EPLC-32
M1 and NCI-H292 cells with (Msh3) and without (Luc) MCRS1 knockdown.
Additional file 2: Top 10 alterations in cellular functions related to
differentially expressed genes after MCRS1 silencing in EPLC-32 M1
cells using GO term analysis.
Additional file 3: Differentially expressed genes related to the EMT
program based on the microarray data of EPLC-32 M1 and
MCRS1-depleted EPLC-32 M1 cells using KEGG analysis.
Additional file 4: Studying relationships between ZO-1, Occludin,
E-cadherin, and DSG2 genes as well as MCRS1 through bioinformatics
analyses and ChIP-PCR assay.
Additional file 5: Differentially expressed miRNAs in EPLC-32 M1
and MCRS1-depleted EPLC-32 M1 cells: known miRNAs.
Additional file 6: Differentially expressed miRNAs in EPLC-32 M1
and MCRS1-depleted EPLC-32 M1 cells: novel miRNAs.
Additional file 7: Potential miRNAs downstream of MCRS1 were
examined by qRT-PCR. Expression of miR-210 (a) and miR-383 (b) in
EPLC-32 M1 and NCI-H292 cells with (Msh3) and without (Luc) MCRS1
knockdown. (Student’s t-test, *P <0.05).
Additional file 8: Heatmap of the differentially expressed miRNAs
in three NSCLC cell lines (A549, 801D, and EPLC-32 M1) compared
to the immortalized human bronchial epithelial cell line (16HBE).
Green, down-regulation; red, up-regulation.
Additional file 9: The seven differentially expressed miRNAs
selected through the integrated analysis of miRNA expression
profiles with miRNA target prediction.
Additional file 10: Schematic diagram illustrating the research
strategy focusing on miR-129*. This study was initially performed to
identify differential miRNAs using the miRNA-sequence method; 7 miRNAs
targeting MCRS1 were predicted using bioinformatics. miR-129* and
miR-1299 were subsequently chosen for further validation because of the
inverse relationship between these two miRNAs and MCRS1 expression.
qRT-PCR assays confirmed that the expression of miR-129* was significantly
down-regulated in NSCLC cell lines.
Additional file 11: The cell lines used in this study.
Additional file 12: The primers used in this study.
Additional file 13: The antibodies used in this study.Abbreviations
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